Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus

Hepatitis C virus (HCV) causes an infectious disease that manifests itself as liver inflammation, cirrhosis, and can lead to the development of liver cancer. Its NS3/4A serine protease is a potent target for drug design and development since it is responsible for cleavage of the scissile peptide bonds in the polyprotein important for the HCV life cycle. Herein, the ligand-target interactions and the binding free energy of the four current NS3/4A inhibitors (boceprevir, telaprevir, danoprevir, and BI201335) were investigated by all-atom molecular dynamics simulations with three different initial atomic velocities. The per-residue free energy decomposition suggests that the key residues involved in inhibitor binding were residues 41-43, 57, 81, 136-139, 155-159, and 168 in the NS3 domain. The van der Waals interactions yielded the main driving force for inhibitor binding at the protease active site for the cleavage reaction. In addition, the highest number of hydrogen bonds was formed at the reactive P1 site of the four studied inhibitors. Although the hydrogen bond patterns of these inhibitors were different, their P3 site was most likely to be recognized by the A157 backbone. Both molecular mechanic (MM)/Poisson-Boltzmann surface area and MM/generalized Born surface area approaches predicted the relative binding affinities of the four inhibitors in a somewhat similar trend to their experimentally derived biological activities.

[1]  McKenzie Ferguson,et al.  Current Therapies for Chronic Hepatitis C , 2011, Pharmacotherapy.

[2]  Thanyada Rungrotmongkol,et al.  Molecular Dynamic Behavior and Binding Affinity of Flavonoid Analogues to the Cyclin Dependent Kinase 6/cyclin D Complex , 2012, J. Chem. Inf. Model..

[3]  Peter W. White,et al.  Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease , 2010, Antimicrobial Agents and Chemotherapy.

[4]  H. Parge,et al.  The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.

[5]  R. De Francesco,et al.  Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. , 2000, Current topics in microbiology and immunology.

[6]  Nopporn Kaiyawet,et al.  Molecular insight into the specific binding of ADP-ribose to the nsP3 macro domains of chikungunya and Venezuelan equine encephalitis viruses: molecular dynamics simulations and free energy calculations. , 2010, Journal of molecular graphics & modelling.

[7]  William McDowell,et al.  Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates. , 2010, Bioorganic & medicinal chemistry letters.

[8]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[9]  Seng-Lai Tan,et al.  Hepatitis C viruses : genomes and molecular biology , 2006 .

[10]  Weiwei Xue,et al.  Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis , 2014, J. Chem. Inf. Model..

[11]  Hong Cao,et al.  The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors , 2012, PLoS pathogens.

[12]  L. Vrang,et al.  In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435 , 2010, Antimicrobial Agents and Chemotherapy.

[13]  Huanxiang Liu,et al.  Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.

[14]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[15]  S. Pricl,et al.  Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. , 2004, Journal of molecular graphics & modelling.

[16]  Tan Sl HCV NS3-4A Serine Protease -- Hepatitis C Viruses: Genomes and Molecular Biology , 2006 .

[17]  A. Hallberg,et al.  Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. , 2001, Bioorganic & medicinal chemistry letters.

[18]  G. Kukolj,et al.  In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335 , 2011, Antimicrobial Agents and Chemotherapy.

[19]  Zhuyan Guo,et al.  Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. , 2007, Journal of medicinal chemistry.

[20]  T. Rungrotmongkol,et al.  Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1. , 2012, Journal of molecular graphics & modelling.

[21]  A. Molla,et al.  Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System , 2007, Antimicrobial Agents and Chemotherapy.

[22]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[23]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[24]  Chao Lin,et al.  HCV NS3-4A Serine Protease , 2006 .

[25]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[26]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[27]  Huanxiang Liu,et al.  Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. , 2012, Molecular bioSystems.

[28]  Vladimı́r Frecera,et al.  Structure-based design of inhibitors of NS 3 serine protease of hepatitis C virus , 2003 .

[29]  S. Lemon,et al.  Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Harper,et al.  The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease. , 2004, Journal of medicinal chemistry.

[31]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[32]  Kai Lin Development of novel antiviral therapies for hepatitis C virus , 2010, Virologica Sinica.

[33]  Wei Zhang,et al.  Prediction of binding for a kind of non-peptic HCV NS3 serine protease inhibitors from plants by molecular docking and MM-PBSA method. , 2007, Bioorganic & medicinal chemistry.

[34]  Nopporn Kaiyawet,et al.  Effect of Halogen Substitutions on dUMP to Stability of Thymidylate Synthase/dUMP/mTHF Ternary Complex Using Molecular Dynamics Simulation , 2013, J. Chem. Inf. Model..

[35]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[36]  M. Rossmann,et al.  Refined structure of Sindbis virus core protein and comparison with other chymotrypsin-like serine proteinase structures. , 1993, Journal of molecular biology.

[37]  M. Murcko,et al.  Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. , 2007, Bioorganic & medicinal chemistry letters.

[38]  T. Darden,et al.  The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .

[39]  C. Schiffer,et al.  Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding , 2010, Proceedings of the National Academy of Sciences.

[40]  S. Locarnini,et al.  Hepatitis C virus resistance to protease inhibitors. , 2011, Journal of hepatology.

[41]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[42]  F. Zoulim,et al.  Current and emerging therapeutic approaches to hepatitis C infection , 2003, Expert review of anti-infective therapy.

[43]  T. Lin,et al.  Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. , 2008, Journal of molecular graphics & modelling.

[44]  O. Hucke,et al.  Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335* , 2011, The Journal of Biological Chemistry.

[45]  Dylan P. Hartley,et al.  Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.

[46]  T. Mahmood,et al.  An overview about hepatitis C: A devastating virus , 2010, Critical reviews in microbiology.

[47]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[48]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[49]  C. Taft,et al.  Computer-Assisted Analysis of the Interactions of Macrocyclic Inhibitors with wild Type and Mutant D168A Hepatitis C Virus NS3 Serine Protease , 2006 .

[50]  R. De Francesco,et al.  Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus , 1998, Journal of Virology.

[51]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[52]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..